Annual CFF
$21.04 M
+$20.56 M+4291.86%
December 31, 2023
Summary
- As of February 22, 2025, TRDA annual cash flow from financing activities is $21.04 million, with the most recent change of +$20.56 million (+4291.86%) on December 31, 2023.
- During the last 3 years, TRDA annual CFF has fallen by -$29.05 million (-58.00%).
- TRDA annual CFF is now -93.16% below its all-time high of $307.46 million, reached on December 31, 2021.
Performance
TRDA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$11.00 K
-$101.38 M-100.01%
September 30, 2024
Summary
- As of February 22, 2025, TRDA quarterly cash flow from financing activities is -$11.00 thousand, with the most recent change of -$101.38 million (-100.01%) on September 30, 2024.
- Over the past year, TRDA quarterly CFF has dropped by -$379.00 thousand (-102.99%).
- TRDA quarterly CFF is now -100.01% below its all-time high of $190.75 million, reached on December 31, 2021.
Performance
TRDA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$102.25 M
-$379.00 K-0.37%
September 30, 2024
Summary
- As of February 22, 2025, TRDA TTM cash flow from financing activities is $102.25 million, with the most recent change of -$379.00 thousand (-0.37%) on September 30, 2024.
- Over the past year, TRDA TTM CFF has increased by +$81.55 million (+393.85%).
- TRDA TTM CFF is now -66.74% below its all-time high of $307.46 million, reached on December 31, 2021.
Performance
TRDA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TRDA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4291.9% | -103.0% | +393.9% |
| 3 y3 years | -58.0% | -103.1% | +10000.0% |
| 5 y5 years | +10000.0% | -103.1% | +10000.0% |
TRDA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -93.2% | +4291.9% | -100.0% | at low | -66.7% | >+9999.0% |
| 5 y | 5-year | -93.2% | >+9999.0% | -100.0% | at low | -66.7% | >+9999.0% |
| alltime | all time | -93.2% | >+9999.0% | -100.0% | at low | -66.7% | >+9999.0% |
Entrada Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.00 K(-100.0%) | $102.25 M(-0.4%) |
| Jun 2024 | - | $101.37 M(>+9900.0%) | $102.63 M(+5912.4%) |
| Mar 2024 | - | $206.00 K(-70.1%) | $1.71 M(-91.9%) |
| Dec 2023 | $21.04 M(+4291.9%) | $690.00 K(+87.5%) | $21.04 M(+1.6%) |
| Sep 2023 | - | $368.00 K(-16.9%) | $20.70 M(+1.5%) |
| Jun 2023 | - | $443.00 K(-97.7%) | $20.40 M(+2.2%) |
| Mar 2023 | - | $19.54 M(+5357.0%) | $19.96 M(+4068.1%) |
| Dec 2022 | $479.00 K | $358.00 K(+496.7%) | $479.00 K(-99.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | $60.00 K(+445.5%) | $190.88 M(-0.0%) |
| Jun 2022 | - | $11.00 K(-78.0%) | $190.92 M(-0.1%) |
| Mar 2022 | - | $50.00 K(-100.0%) | $191.13 M(-37.8%) |
| Dec 2021 | $307.46 M(+513.8%) | $190.75 M(>+9900.0%) | $307.46 M(+163.4%) |
| Sep 2021 | - | $106.00 K(-50.7%) | $116.71 M(+0.1%) |
| Jun 2021 | - | $215.00 K(-99.8%) | $116.60 M(+0.2%) |
| Mar 2021 | - | $116.39 M | $116.39 M |
| Dec 2020 | $50.09 M(>+9900.0%) | - | - |
| Dec 2019 | $38.00 K | - | - |
FAQ
- What is Entrada Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Entrada Therapeutics?
- What is Entrada Therapeutics annual CFF year-on-year change?
- What is Entrada Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly CFF year-on-year change?
- What is Entrada Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Entrada Therapeutics?
- What is Entrada Therapeutics TTM CFF year-on-year change?
What is Entrada Therapeutics annual cash flow from financing activities?
The current annual CFF of TRDA is $21.04 M
What is the all time high annual CFF for Entrada Therapeutics?
Entrada Therapeutics all-time high annual cash flow from financing activities is $307.46 M
What is Entrada Therapeutics annual CFF year-on-year change?
Over the past year, TRDA annual cash flow from financing activities has changed by +$20.56 M (+4291.86%)
What is Entrada Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TRDA is -$11.00 K
What is the all time high quarterly CFF for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly cash flow from financing activities is $190.75 M
What is Entrada Therapeutics quarterly CFF year-on-year change?
Over the past year, TRDA quarterly cash flow from financing activities has changed by -$379.00 K (-102.99%)
What is Entrada Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TRDA is $102.25 M
What is the all time high TTM CFF for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM cash flow from financing activities is $307.46 M
What is Entrada Therapeutics TTM CFF year-on-year change?
Over the past year, TRDA TTM cash flow from financing activities has changed by +$81.55 M (+393.85%)